Menu

MD Anderson Cancer Center Head Resigns

Ronald DePinho tells institute employees it is “time for a change in leadership.”

Mar 9, 2017
Tracy Vence

The University of Texas MD Anderson Cancer Center president is stepping down. Ronald DePinho, who has led the institution for nearly six years and was involved in managerial and financial controversies, wrote in a letter to his staff that it is “time for a change in leadership.”

As the Houston Chronicle noted, “DePinho’s [leadership] at MD Anderson was marked by change, criticism, and challenges.” In March 2013, for example, around one-third of institute employees who responded to a survey indicated dissatisfaction with his management. That May, The Cancer Letter reported that the institute spent around $1.5 million in building renovations for DePinho’s wife, Lydia Chin, chair of MD Anderson’s genomic medicine department. The institute disputed the report at the time.

In 2016, the institute reported significant operating losses. MD Anderson “was expecting to lose as much as $450 million in 2017,” STAT News reported, “though it brings in about $4 billion in annual revenue.”

“In an era of significant and rapid financial change, we are recovering well from short-term challenges and, longer term, have diversified our revenue streams through philanthropy, strategic ventures and innovation,” DePinho wrote in his letter, adding: “I could have done a better job administratively, a better job listening, a better job communicating. Forgive me for my short comings [sic].”

THUMBNAIL IMAGE: WIKIMEDIA, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.